Pharmaceutical combination comprising TNO155 and ribociclib
US12343344B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 10, 2020 |
| Grant date | Jul 1, 2025 |
| Priority date | — |
| Expiry date | Jun 30, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical combination comprising TNO155 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in a SHP2 inhibitor combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.